Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al.

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).